184 related articles for article (PubMed ID: 27519631)
1. Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study.
Zhang L; Li Y; Lan L; Liu R; Wu Y; Qu Q; Wen K
Mol Cell Endocrinol; 2016 Dec; 437():51-61. PubMed ID: 27519631
[TBL] [Abstract][Full Text] [Related]
2. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
[TBL] [Abstract][Full Text] [Related]
3. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
Kilker RL; Planas-Silva MD
Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
[TBL] [Abstract][Full Text] [Related]
6. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).
Cirillo F; Lappano R; Bruno L; Rizzuti B; Grande F; Guzzi R; Briguori S; Miglietta AM; Nakajima M; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Aug; 38(1):335. PubMed ID: 31370872
[TBL] [Abstract][Full Text] [Related]
7. Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.
Li Y; Jia Y; Bian Y; Tong H; Qu J; Wang K; Wan XP
Cell Commun Signal; 2019 Mar; 17(1):22. PubMed ID: 30836961
[TBL] [Abstract][Full Text] [Related]
8. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
9. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
10. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation.
Catalano S; Giordano C; Rizza P; Gu G; Barone I; Bonofiglio D; Giordano F; Malivindi R; Gaccione D; Lanzino M; De Amicis F; Andò S
J Cell Physiol; 2009 Mar; 218(3):490-500. PubMed ID: 18988190
[TBL] [Abstract][Full Text] [Related]
11. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Chen C; Wang Y; Wang S; Liu Y; Zhang J; Xu Y; Zhang Z; Bao W; Wu S
Int J Oncol; 2017 Mar; 50(3):942-952. PubMed ID: 28098854
[TBL] [Abstract][Full Text] [Related]
12. GPER/ERK&AKT/NF-κB pathway is involved in cadmium-induced proliferation, invasion and migration of GPER-positive thyroid cancer cells.
Zhu P; Liao LY; Zhao TT; Mo XM; Chen GG; Liu ZM
Mol Cell Endocrinol; 2017 Feb; 442():68-80. PubMed ID: 27940299
[TBL] [Abstract][Full Text] [Related]
13. Arsenite and Cadmium Activate MAPK/ERK via Membrane Estrogen Receptors and G-Protein Coupled Estrogen Receptor Signaling in Human Lung Adenocarcinoma Cells.
Huff MO; Todd SL; Smith AL; Elpers JT; Smith AP; Murphy RD; Bleser-Shartzer AS; Hoerter JE; Radde BN; Klinge CM
Toxicol Sci; 2016 Jul; 152(1):62-71. PubMed ID: 27071941
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells.
Zhang H; Wang X; Chen Z; Wang W
Cell Mol Biol (Noisy-le-grand); 2015 Nov; 61(7):96-101. PubMed ID: 26638889
[TBL] [Abstract][Full Text] [Related]
15. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
16. Casein kinase 1 controls the shuttling of epidermal growth factor receptor and estrogen receptor in endometrial carcinoma induced by breast cancer hormonal therapy: Relevance of GPER1/Src.
Hoang LN; Lee SJ
Cell Signal; 2023 Aug; 108():110733. PubMed ID: 37257767
[TBL] [Abstract][Full Text] [Related]
17. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.
Du GQ; Zhou L; Chen XY; Wan XP; He YY
Biochem Biophys Res Commun; 2012 Apr; 420(2):343-9. PubMed ID: 22425989
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
19. TET1-GPER-PI3K/AKT pathway is involved in insulin-driven endometrial cancer cell proliferation.
Xie BY; Lv QY; Ning CC; Yang BY; Shan WW; Cheng YL; Gu C; Luo XZ; Zhang ZB; Chen XJ; Xi XW; Feng YJ
Biochem Biophys Res Commun; 2017 Jan; 482(4):857-862. PubMed ID: 27889612
[TBL] [Abstract][Full Text] [Related]
20. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling.
Santolla MF; De Francesco EM; Lappano R; Rosano C; Abonante S; Maggiolini M
Cell Signal; 2014 Jul; 26(7):1466-75. PubMed ID: 24662263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
